24/7 Market News Snapshot 23 October, 2024 – BioVie, Inc. Common Stock (NASDAQ:BIVI)

DENVER, Colo., 23 October, 2024 (247marketnews.com) – (NASDAQ:BIVI) are discussed in this article.
BioVie Inc. (NASDAQ:BIVI), a clinical-stage company specializing in innovative therapies for chronic illnesses, has witnessed a significant decline in its market price, currently trading at approximately $3.11, down 7.32% from the previous close of $3.36. Despite this downward trend, the stock has attracted considerable trading volume today, reaching 29.71 million shares, indicating heightened investor interest. Market analysts suggest observing key technical levels, with support around $3.00 and resistance anticipated at $3.50, as these may influence short-term price movements.

In tandem with its performance in the market, BioVie has announced the pricing of a registered direct offering of 2,667,000 shares of its common stock, set at $2.25 per share, which is anticipated to yield gross proceeds of approximately $6 million before expenses. The offering includes a concurrent private placement of unregistered warrants for the purchase of an additional 2,667,000 shares, at an exercise price of $2.12 per share, with the warrants becoming exercisable six months post-issuance and expiring five years thereafter. This funding is earmarked for working capital and to support the Company’s ongoing clinical initiatives.

The completion of both the registered direct offering and the private placement is expected on or about October 24, 2024, subject to customary closing conditions, with ThinkEquity acting as the sole placement agent. BioVie focuses on addressing unmet medical needs in neurological disorders, including Long COVID, Alzheimer’s, and Parkinson’s diseases, while also developing therapies for advanced liver disease. The company remains dedicated to its mission of enhancing the quality of life for patients suffering from chronic conditions through innovative therapeutic solutions.

Related news for (BIVI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.